Phathom Pharmaceuticals, Inc.
PHATHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Phathom Pharmaceuticals, Inc. (PHAT) is listed under Biotechnology. The $768.6M market capitalization puts PHAT squarely in small-cap range for its industry. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Market Cap
$768.6M
Beta
0.51
P/E (TTM)
—
P/E (Fwd)
8.56
EPS (TTM)
$-1.25
EPS (Fwd)
$1.11
ROE
—
ROA
-8.8%
Cash
$182.5M
Total Debt
$552.0M
Free CF
-$32.6M
52W Change
-26.3%
Annual Financials
Cash vs Debt
Where PHAT stands vs its 150-day and 200-day moving averages
As of the August 19, 2026 close, PHAT finished 19.28% below its 150-day moving average ($11.46) and 25.28% below its 200-day moving average ($12.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PHAT overbought or oversold?
At the August 19, 2026 close, PHAT's RSI(14) was 28.9, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, PHAT has $182.5M in cash with $552.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$32.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
PHAT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Phathom Pharmaceuticals, Inc. and its sector.